Literature DB >> 21732533

High dose of dietary resveratrol enhances insulin sensitivity in healthy rats but does not lead to metabolite concentrations effective for SIRT1 expression.

Gaby Andersen1, Alexander Burkon, Florian J Sulzmaier, Joel M Walker, Gunhild Leckband, Rainer Fuhst, Helmut F Erbersdobler, Veronika Somoza.   

Abstract

SCOPE: trans-Resveratrol has been shown to improve insulin sensitivity and to enhance cellular glucose uptake. Evidence from recent studies indicates that these effects depend on SIRT1-pathways. METHODS AND
RESULTS: Since ingestion of resveratrol leads to the presence of resveratrol and resveratrol metabolites in the body, we aimed at investigating (i) whether a daily dose of 300 mg resveratrol/kg body weight in healthy male Wistar rats for a period of 8 wk affects the selected parameters of glucose and lipid metabolism and (ii) whether the resulting plasma concentrations of resveratrol metabolites were effective in modulating SIRT1 expression. The dietary dose was based on the results from preceding toxicity studies. The results from the feeding experiment revealed plasma concentrations of resveratrol and its metabolites below 1 μmol/L and showed that fasting glucose and insulin levels were decreased by 35 and 41%, respectively, in the resveratrol group compared with controls. Insulin sensitivity was enhanced by 70%, whereas liver SIRT1 protein expression was not affected. Treatment of HepG2 cells with 10 μM resveratrol (1.49-fold) or its diglucuronides (1.21-fold) increased SIRT1 expression.
CONCLUSION: These results suggest that the improved insulin sensitivity after dietary administration of 300 mg resveratrol/kg body weight does not involve increased protein expression of SIRT1.
Copyright © 2011 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21732533     DOI: 10.1002/mnfr.201100292

Source DB:  PubMed          Journal:  Mol Nutr Food Res        ISSN: 1613-4125            Impact factor:   5.914


  6 in total

Review 1.  Effects of resveratrol in experimental and clinical non-alcoholic fatty liver disease.

Authors:  Sara Heebøll; Karen Louise Thomsen; Steen B Pedersen; Hendrik Vilstrup; Jacob George; Henning Grønbæk
Journal:  World J Hepatol       Date:  2014-04-27

Review 2.  Resveratrol and clinical trials: the crossroad from in vitro studies to human evidence.

Authors:  Joao Tomé-Carneiro; Mar Larrosa; Antonio González-Sarrías; Francisco A Tomás-Barberán; María Teresa García-Conesa; Juan Carlos Espín
Journal:  Curr Pharm Des       Date:  2013       Impact factor: 3.116

3.  Reduction of Cognitive Decline in Patients with or at High Risk for Diabetes.

Authors:  Gladys E Maestre
Journal:  Curr Geriatr Rep       Date:  2017-07-18

4.  Regulation of neurons in the dorsal motor nucleus of the vagus by SIRT1.

Authors:  Yanyan Jiang; Andrea Zsombok
Journal:  Front Neurosci       Date:  2014-01-10       Impact factor: 4.677

5.  High-dose resveratrol supplementation in obese men: an investigator-initiated, randomized, placebo-controlled clinical trial of substrate metabolism, insulin sensitivity, and body composition.

Authors:  Morten M Poulsen; Poul F Vestergaard; Berthil F Clasen; Yulia Radko; Lars P Christensen; Hans Stødkilde-Jørgensen; Niels Møller; Niels Jessen; Steen B Pedersen; Jens Otto L Jørgensen
Journal:  Diabetes       Date:  2012-11-28       Impact factor: 9.461

6.  An examination of resveratrol's mechanisms of action in human tissue: impact of a single dose in vivo and dose responses in skeletal muscle ex vivo.

Authors:  Cameron B Williams; Meghan C Hughes; Brittany A Edgett; Trisha D Scribbans; Craig A Simpson; Christopher G R Perry; Brendon J Gurd
Journal:  PLoS One       Date:  2014-07-14       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.